Main baseline characteristics of the APL93 patients at the time of inclusion in the entire cohort and in the cohort of patients studied
| . | Overall cohort (499 patients) . | Patients studied (77 patients) . |
|---|---|---|
| Male gender | 239 (50%) | 40 (52%) |
| Age, y | 45 (33-57) | 44 (31-51) |
| WBC count, × 109/L | 2.8 (1.2-11.7) | 6.7 (1.9-26.7) |
| Platelet count, × 109/L | 31 (17-55) | 28.5 (19-45) |
| Fibrinogen level, μM | 4.7 (3.2-7.3) | 4.1 (2.6-5.5) |
| Induction group | ||
| ATRA followed by CT | 124 (25%) | 12 (15%) |
| ATRA plus CT | 133 (27%) | 15 (20%) |
| High WBC (ATRA + CT) | 194 (39%) | 46 (59%) |
| Elderly group | 48 (9%) | 4 (5%) |
| Maintenance | ||
| Continuous low-dose CT | 102 (29%) | 16 (29%) |
| ATRA | 76 (21%) | 16 (29%) |
| ATRA + CT | 100 (28%) | 9 (17%) |
| None | 79 (22%) | 14 (25%) |
| . | Overall cohort (499 patients) . | Patients studied (77 patients) . |
|---|---|---|
| Male gender | 239 (50%) | 40 (52%) |
| Age, y | 45 (33-57) | 44 (31-51) |
| WBC count, × 109/L | 2.8 (1.2-11.7) | 6.7 (1.9-26.7) |
| Platelet count, × 109/L | 31 (17-55) | 28.5 (19-45) |
| Fibrinogen level, μM | 4.7 (3.2-7.3) | 4.1 (2.6-5.5) |
| Induction group | ||
| ATRA followed by CT | 124 (25%) | 12 (15%) |
| ATRA plus CT | 133 (27%) | 15 (20%) |
| High WBC (ATRA + CT) | 194 (39%) | 46 (59%) |
| Elderly group | 48 (9%) | 4 (5%) |
| Maintenance | ||
| Continuous low-dose CT | 102 (29%) | 16 (29%) |
| ATRA | 76 (21%) | 16 (29%) |
| ATRA + CT | 100 (28%) | 9 (17%) |
| None | 79 (22%) | 14 (25%) |
For quantitative variables, data are given as medians (with the 25th to 75th percentiles in parentheses), while for qualitative variables, data are given as number of patients (percentages).
WBC indicates white blood cell; ATRA, all-trans retinoic acid; CT, daunorubicin-AraC chemotherapy.